Findings from this single-arm Phase 2 study provide encouraging data for the potential use of Nexavar in combination with docetaxel and cisplatin to treat patients with metastatic/advanced gastric/GEJ adenocarcinoma. The most common treatment-emergent adverse events included neutropenia, fatigue, anorexia, hand-foot reaction, nausea, diarrhea and dehydration.
The lead investigator for this study is Weijing Sun, MD, assistant professor of medicine, University of Pennsylvania, director of the Upper GI and Pancreatic-Biliary-Hepatic Cancer Group and the associate director of the GI Cancer Program. (abstract #4535).
Phase 2 Trial of Sorafenib in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
Preliminary findings from this Phase 2 study suggest that Nexavar is active and tolerated in patients with recurrent epithelial ovarian cancer. The most common treatment-emergent adverse events were dermatologic and metabolic.
The lead investigator for this study is Daniela Matei, M.D., Ph.D., assistant professor, department of medicine, Walther Oncology Center, Indiana University, Bloomington, IN. (abstract #5537).
"We continue to be encouraged by Nexavar's potential activity as a single agent or in combination with other chemotherapeutic agents in these early stage clinical trials in tumor types with high unmet treatment needs," said Susan Kelley, MD, vice president, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. "The more data we compile from various studies in multiple tumor types, the better informed we are to determine the appropriate direction for further development of Nexavar in additional clinical cancer settings."
Nexavar's Differentiated Mechanism
Nexavar targets both the tumor cell and tumor vasculature. In
preclinical studies, Nexavar has be
|SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved